Melanoma is an increasingly common diagnosis. Unlike many other cancers, melanoma does not respond to traditional chemotherapy or radiation. Because treatment options are limited, there is a significant need for pharmaceutical research and development. It is important for clinicians to understand the basics principles of molecular diagnostics in melanoma in order to facilitate the most current and efficacious treatment for their patients. Before ordering molecular testing, clinicians should consider the type of melanoma (e.g., cutaneous versus acral) and whether there are any metastases.

Adroit Market Research study on the global market for melanoma diagnostics offers a holistic view of the industry, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2020 and a projection from 2021 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global melanoma diagnostics market have been analyzed in depth.

Melanoma represents the most lethal type of skin cancer, with an estimated 7000 deaths in 2019 in the United States. Furthermore, its incidence has steadily risen since the 1960s, with approximately 96,000 new cases in 2019. Ultraviolet radiation (UVR) represents a major contributor to cutaneous melanomagenesis through its deleterious effects on the skin and direct damage to DNA. These processes trigger the acceleration of tumorigenesis and thus have facilitated the emergence of malignant melanoma as a significant public health problem. The financial burden of treating melanoma remains cumbersome. In the United States, the estimated annual cost per patient for Stage I melanoma is $2169–$14,499, while the cost for Stage IV melanoma is $34,103–$152,244. While the advent of new immunotherapies has helped to reduce the mortality rate over the last decade, melanoma remains difficult to treat. Given the expensive costs for treatment of advanced-stage melanoma, diagnosing and treating melanoma at an early stage is crucial. However, the heterogeneous morphological and histopathological appearance of these tumors can make diagnosis challenging.

The key players of global melanoma diagnostics market report include Myriad Genetic Laboratories Inc., AB Sciences, Aruplabs, Incyte, Dermtech, Amgen, Roche, Foundation Medical Incorporation, Abbott, Wipro among others.

Key Segments of the Global Melanoma Diagnostics Market

Test Type Overview, 2018-2028 (USD Million)

• Biopsy
• Imaging
• Other

End User Overview, 2018-2028 (USD Million)

• Hospitals
• Dermatology Clinics
• Diagnostic Laboratories

Regional Overview, 2018-2028 (USD Million)

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Middle East and Africa

• GCC
• South Africa
• Rest of Middle East and Africa

South America

• Brazil
• Mexico
• Rest of South America